In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Bio-hybrid robot made from langoustine shells works like arcade claw crane
In Switzerland, scientists at École Polytechnique Fédérale de Lausanne have converted shellfish shells into claws that grip, not unlike the prize-filled claw machines found...
Holy Carp! makes waves as biodegradable single-use soy sauce alternative
In Australia, design studios Heliograf and Vert Design have jointly developed a biodegradable alternative to whimsical—but polluting—plastic fish-shaped soy sauce containers often seen with...
Pineapple hair ties win Fowler Business Concept Challenge
In California, a University of San Diego graduate student has won a $15,000 scholarship to advance her pineapple leaf hair ties.
Sage Dobby, who...